Advanced Therapeutics最新文献_第2页

Applications of Nanomaterial-Microorganism Hybrid Systems in the Treatment of Tumor 纳米材料-微生物混合系统在肿瘤治疗中的应用

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-21 DOI: 10.1002/adtp.202400425

Muskan Saif Khan, Mirza Albash Baig, Meng Tian, Bowen Li, Guoqing Feng, Run Yang, Yang Bai, Bin Zheng

{"title":"Applications of Nanomaterial-Microorganism Hybrid Systems in the Treatment of Tumor","authors":"Muskan Saif Khan, Mirza Albash Baig, Meng Tian, Bowen Li, Guoqing Feng, Run Yang, Yang Bai, Bin Zheng","doi":"10.1002/adtp.202400425","DOIUrl":"https://doi.org/10.1002/adtp.202400425","url":null,"abstract":"Recent advances in cancer treatments such as targeted therapy and immunotherapy, have brought hope for curing a variety of cancers. However, there are ongoing challenges such as poor targeting, biocompatibility and biosafety. Engineered bacteria can cope with these problems, providing a unique therapeutic approach for the treatment of tumors. Nanotechnology offers the potential to modify the surface of bacteria, and the use of biofilm and coating technology to physically encapsulate bacteria can help bacteria escape the host immune system and improve the efficiency and safety of drug delivery. Synthetic biology and genetic engineering technologies can treat bacteria as “robotic factories” to produce and deliver anti-cancer drugs, including anti-tumor cytokines, immunomodulators, prodrug enzymes, and so on, according to clinical needs. Engineered bacteria therapies can be used either as monotherapy or in combination with other anticancer therapies to achieve better clinical outcomes. In this review, it introduce and summarize the processing and modification methods of engineered bacteria for cancer targeted therapy, and summarize and analyze the current clinical trials of engineered bacteria for cancer targeted therapy.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self-Assembled Nanocarriers of Synthetic and Natural Plasmalogens for Potential Nanomedicine Development (Adv. Therap. 2/2025) 用于潜在纳米药物开发的合成和天然缩醛原自组装纳米载体（Adv. therapy . 2/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-13 DOI: 10.1002/adtp.202570004

Yu Wu, Borislav Angelov, Yuru Deng, Takehiko Fujino, Md Shamim Hossain, Thomas Bizien, Angelina Angelova

引用次数: 0

Issue Information (Adv. Therap. 2/2025) 发行信息（ad . therapy . 2/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-13 DOI: 10.1002/adtp.202570005

引用次数: 0

Photothermal Therapy: From Encouraging Lab Results to Lackluster Clinical Translation 光热疗法：从令人鼓舞的实验室结果到平淡的临床转化

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-09 DOI: 10.1002/adtp.202400347

Jonathan Buiel, Jordan Robert, Dikran Mekhjian, Deepak S. Chauhan, Xavier Banquy

{"title":"Photothermal Therapy: From Encouraging Lab Results to Lackluster Clinical Translation","authors":"Jonathan Buiel, Jordan Robert, Dikran Mekhjian, Deepak S. Chauhan, Xavier Banquy","doi":"10.1002/adtp.202400347","DOIUrl":"https://doi.org/10.1002/adtp.202400347","url":null,"abstract":"Cancer is a pervasive and complex disease that poses a significant threat to public health worldwide. The prevalent therapeutic options, including chemotherapy and radiotherapy, pose detrimental side effects. Consequently, non-invasive and selective therapeutic strategies are sought, such as nanoparticle-mediated photothermal therapy (PTT). This technique employs benign photothermal agents that gather within tumors post-injection. Under near-infra-red light exposure, these agents induce localized hyperthermia, killing tumor cells. Here, the laboratory development, recent advances, and clinical status of photothermal therapy are examined. Despite two decades of development, photothermal therapy has yielded few clinical trials. A standout agent, the gold nanoshell, holds promise for prostate cancer treatment as the only one in human clinical trials. To provide context, PTT is compared to photodynamic therapy, which has over 250 human trials in 40 years, highlighting the need to bridge the gap for effective photothermal therapy translation. Therefore, we delve into the gap of clinical implementation between photothermal therapy and similar technologies, such as photodynamic therapy, laser interstitial thermal therapy, and cancer nanomedicines, offering insights and potential solutions.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Copper Ions in Mediating the Anti-Cancer Effects Using Nanomaterials 铜离子在纳米材料抗癌中的作用

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-03 DOI: 10.1002/adtp.202400426

Irfan Mehmud, Song Wu, Shaohua Zhang

{"title":"The Role of Copper Ions in Mediating the Anti-Cancer Effects Using Nanomaterials","authors":"Irfan Mehmud, Song Wu, Shaohua Zhang","doi":"10.1002/adtp.202400426","DOIUrl":"https://doi.org/10.1002/adtp.202400426","url":null,"abstract":"Copper plays a pivotal role in human physiology, particularly in oncology, acting both as a facilitator of progression and also as a potential avenue for advanced therapeutic approaches. Maintaining copper homeostasis is crucial. The dysregulation of copper homeostasis is implicated in tumor growth through its involvement in critical processes of angiogenesis, proliferation, and metastasis. The elevation in copper level in the tumor microenvironment (TME) activates oncogenic pathways to drive the neovascularization and sustained growth of malignancies. However, the same reliance on copper offers a unique weakness that can be leveraged for innovative therapeutic interventions. The recent advances in nanomedicine enable the synthesis of nanostructures that can help modulate the level of copper with precision offering multifaceted approaches for copper-based cancer therapy with controlled release mechanism, optimized structures to induce cuproptosis, selective eradication of cancer cells with minimum and systemic toxicity. This review explores the dual role of copper in cancer biology, emphasizing its contribution to the progression of tumors and its emerging application in targeted cancer therapy. The review also highlights the potential of nanostructures in harnessing copper-based therapies and their transformative potential from bench to bed side with novel, highly effective, and clinical safety.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eltrombopag Inhibited Liver Cancer by Enhancing SMYD4 Protein Degradationvia TRIP12 Ubiquitinase Eltrombopag通过TRIP12泛素酶促进SMYD4蛋白降解抑制肝癌

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-03 DOI: 10.1002/adtp.202400372

Jiale Li, Qiqiang Zhang, Chunyan Wang, Shupeng Liu

{"title":"Eltrombopag Inhibited Liver Cancer by Enhancing SMYD4 Protein Degradationvia TRIP12 Ubiquitinase","authors":"Jiale Li, Qiqiang Zhang, Chunyan Wang, Shupeng Liu","doi":"10.1002/adtp.202400372","DOIUrl":"https://doi.org/10.1002/adtp.202400372","url":null,"abstract":"According to prior studies, SET and MYND domain-containing protein 4 (SMYD4) is involved in tumor progression and metastasis, representing a potential therapeutic target for tumors. However, no specific inhibitors or drugs targeting SMYD4 are currently available. In this study, molecular docking and molecular dynamics simulations were used to screen small molecule lead compounds binding to SMYD4 protein. CCK8 assay, colony formation assay, EdU assay were used to analyze the viability and proliferation of tumor cells. Flow cytometric analysis was used to evaluate cell apoptosis and cell cycle. Clorazepate, Ativan, Darifenacin and Eltrombopag were found to bind with SMYD4 with the highest probability and to meet the five principles of the drug class. Molecular dynamics simulations showed that Eltrombopag had the strongest binding capacity to SMYD4 protein. The functional analysis showed that Eltrombopag inhibited hepatocellular carcinoma cell proliferation and promoted apoptosis in vivo and in vitro at low density. Moreover, Eltrombopag enhanced ubiquitination of SMYD4 protein and promoted its degradation via thyroid hormone receptor interactor 12(TRIP12). These findings suggest that Eltrombopag is a potential inhibitor of SMYD4 protein, representing a novel leading compound for SMYD4 and applied for tumor treatment.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermal Substitutes for Clinical Management of Severe Burn Injuries: Current and Future Perspectives 严重烧伤临床治疗的皮肤替代品：当前和未来的观点

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-23 DOI: 10.1002/adtp.202400455

Van Vo, Hanif Haidari, Allison J. Cowin, Marcus Wagstaff, Bronwyn Dearman, Zlatko Kopecki

{"title":"Dermal Substitutes for Clinical Management of Severe Burn Injuries: Current and Future Perspectives","authors":"Van Vo, Hanif Haidari, Allison J. Cowin, Marcus Wagstaff, Bronwyn Dearman, Zlatko Kopecki","doi":"10.1002/adtp.202400455","DOIUrl":"https://doi.org/10.1002/adtp.202400455","url":null,"abstract":"Despite significant advances in recent decades, severe burns remain a formidable challenge, with high morbidity and mortality rates. The immunocompromised state following severe burn injuries, compounded by the loss of the protective skin barrier, increases the risk of bacterial colonization and invasion. Without appropriate management, infections in burn patients can progress to sepsis, a life-threatening complication. Current burn care often fails to achieve optimal tissue regeneration and infection prevention, necessitating a combination of different approaches. Developing innovative and safer strategies to mitigate burn infections is essential for improving patient outcomes. This review provides updated insights into various biomaterials tailored for managing infections in severe burns, offering comprehensive insights and a summary of emerging technologies for potential clinical application. Additionally, an in-depth discussion on current research and clinical areas that warrant further investigation is presented. Potential avenues for next-generation dermal substitutes aimed at improving regeneration and preventing burn wound infections are then explored.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400455","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting VEGF-A in an Immunocompetent Orthotopic Mouse Model of Mesenchymal Glioblastoma Improves Antitumorigenicity and Decreases Proinflammatory Response in Normal Brain Tissue after Fractionated Radiotherapy 靶向VEGF-A的免疫功能小鼠间充质胶质母细胞瘤模型可提高正常脑组织分步放疗后的抗肿瘤性并降低促炎反应

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-23 DOI: 10.1002/adtp.202400374

Alexander Edward Nieto, Daniel Felix Fleischmann, Kristian Unger, Valerie Albrecht, Jessica Maas, Horst Zitzelsberger, Claus Belka, Martin Proescholdt, Kirsten Lauber, Maximilian Niyazi, Michael Orth

{"title":"Targeting VEGF-A in an Immunocompetent Orthotopic Mouse Model of Mesenchymal Glioblastoma Improves Antitumorigenicity and Decreases Proinflammatory Response in Normal Brain Tissue after Fractionated Radiotherapy","authors":"Alexander Edward Nieto, Daniel Felix Fleischmann, Kristian Unger, Valerie Albrecht, Jessica Maas, Horst Zitzelsberger, Claus Belka, Martin Proescholdt, Kirsten Lauber, Maximilian Niyazi, Michael Orth","doi":"10.1002/adtp.202400374","DOIUrl":"https://doi.org/10.1002/adtp.202400374","url":null,"abstract":"Glioblastoma is the most aggressive primary brain tumor characterized by a dismal prognosis and a profound therapy resistance that is most evident for the mesenchymal molecular subtype of glioblastoma. Targeting vascular endothelial growth factor (VEGF)-A by the monoclonal antibody bevacizumab, despite failing to improve survival in randomized trials, yields relevant benefits in glioblastoma patients such as reduction of radionecrosis, an adverse event associated with radiotherapy. This demands for continued research to identify optimal combinations of anti-VEGF-A and standard therapies for glioblastoma treatment. We show here that blocking VEGF-A in an immune competent orthotopic glioblastoma mouse model resembling the adverse mesenchymal molecular subtype increases the tumoricidal effect of computed tomography (CT)-based fractionated radiotherapy and also rectifies irradiation-induced expression of genes with known association to mesenchymal subtype enrichment as revealed by microarray-based transcriptome analyses of explanted tumors. VEGF-A blockade also decreases the expression of myeloid-cell-related gene patterns in irradiated tumors and lowers inflammatory response in normal brain tissue after tumor irradiation. Hence, these data both provide a hint how blockade of VEGF-A increases the effect of radiotherapy in mesenchymal glioblastoma and a mechanistic base for clinical observations reporting reduced incidences of radionecrosis in glioblastoma patients treated with radiotherapy upon concurrent administration of bevacizumab.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400374","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143397349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disease-Adaptive Drug Delivery to the Inflamed Intestinal Mucosa Using Poly(Lactic-Co-Glycolic Acid)-cyclodextrin Hybrid Nanocarriers 利用聚（乳酸-共聚甘醇酸）-环糊精混合纳米载体向炎症肠黏膜进行疾病适应性给药

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-19 DOI: 10.1002/adtp.202400368

Jonas Schreiner, Felix E. B. Brettner, Sebastian Steigert, Annika Haessler, Raf Mols, Stefanie Gier, Nathalie Jung, Sarah Vogel-Kindgen, Susanne Muschert, Patrick Augustijns, Maike Windbergs

{"title":"Disease-Adaptive Drug Delivery to the Inflamed Intestinal Mucosa Using Poly(Lactic-Co-Glycolic Acid)-cyclodextrin Hybrid Nanocarriers","authors":"Jonas Schreiner, Felix E. B. Brettner, Sebastian Steigert, Annika Haessler, Raf Mols, Stefanie Gier, Nathalie Jung, Sarah Vogel-Kindgen, Susanne Muschert, Patrick Augustijns, Maike Windbergs","doi":"10.1002/adtp.202400368","DOIUrl":"https://doi.org/10.1002/adtp.202400368","url":null,"abstract":"Fluctuating severity of symptoms is a common hallmark of many inflammatory disorders, including inflammatory bowel disease (IBD). Addressing the pH changes during active and resting phases in IBD-affected tissue, a disease-adaptive nanocarrier system is designed for oral administration, enabling pH-dependent local drug release. The hybrid carrier combines poly(lactic-co-glycolic acid) and an amphiphilic cyclodextrin derivative, with physicochemical properties and drug release kinetics controlled by adjusting polymer ratios. The systems exhibited baseline drug release at pH 5 with increased rates at pH 2, which is characteristic of actively inflamed IBD tissue. Assessing the impact of biomolecule adhesion, biocorona formation was studied using ex vivo human intestinal fluids. Corona composition highly depended on the patient's prandial state and the nanocarrier matrix, with proteins predominating in the fasted state and lipids in the fed state. Notably, differences in the attachment of proteins and free fatty acids are detected in the latter. Transport studies using human in vitro models of the inflamed intestine revealed mucosal accumulation, facilitating localized drug delivery and effectively reducing cytokine levels to basal concentrations. This hybrid system highlights the potential of disease-adaptive drug release for inflammatory disease treatment and underscores the impact of biocorona formation on therapeutic performance in the gastrointestinal tract.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathophysiology of IBD as a Key Strategy for Polymeric Nanoparticle Development IBD的病理生理是聚合物纳米颗粒开发的关键策略

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-19 DOI: 10.1002/adtp.202400439

Elena Gardey, Johannes C. Brendel, Andreas Stallmach

{"title":"Pathophysiology of IBD as a Key Strategy for Polymeric Nanoparticle Development","authors":"Elena Gardey, Johannes C. Brendel, Andreas Stallmach","doi":"10.1002/adtp.202400439","DOIUrl":"https://doi.org/10.1002/adtp.202400439","url":null,"abstract":"Inflammatory bowel disease (IBD) is a complex chronic inflammatory disorder of the gastrointestinal (GI) tract with an uncertain etiology. Currently, IBD therapy relies on the induction of clinical remission followed by maintenance therapy using anti-inflammatory drugs and immunosuppressants; however, a definite cure of the disease is still out of scope. Established approaches are characterized by adverse drug-related side effects that can even be potentially life-threatening. In contrast, increased interest and remarkable scientific progress in targeted drug delivery systems offer a promising approach to reduce systemic adverse events, delivering the therapeutic substances only to inflamed tissue. All alteration in gastrointestinal barrier integrity, especially a disturbed epithelial barrier, a unique pattern of the receptors on cell surface and/or an oxidative stress milieu in inflamed areas can be used as effective approaches for targeted and controlled drug delivery. Hence, this review focuses on the pathophysiology of the inflamed GI tract as a potential strategy for targeted polymeric nanoparticles for IBD treatment. Interdisciplinary efforts between the polymeric chemistry and gastroenterology/immunology promise to create novel synergies that improve the development of effective nanoparticle systems with significant clinical impact. In this regard, the current challenges in the clinical translation of promising nanomedicine are also discussed.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0